Merck Receives 3 New Drug Approvals in Japan (MRK)
Merck & Co. (MRK) has just announced it has won approval for its Gardasil cervical cancer vaccine, Zolinza cancer drug and antibiotic Cubicin, to be sold in Japan.
Dividend.com archives (articles more than 30 days old) are only available to Dividend.com Premium subscribers.
Sign up for a Dividend.com Premium account for instant access to article archives, stock ratings on nearly 1,600 dividend-paying stocks, and much more! FREE TRIAL available!
If you are a current Dividend.com Premium subscriber, please click here to log in.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability